Patents by Inventor Deborah Mortensen

Deborah Mortensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210254000
    Abstract: Provided herein are methods for producing engineered T cells that express a recombinant receptor, such as for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion, in which one or more steps is carried out in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, cultivation is performed in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, the provided methods produce genetically engineered T cells with improved persistence and/or anti-tumor activity in vivo.
    Type: Application
    Filed: November 1, 2018
    Publication date: August 19, 2021
    Applicants: Juno Therapeutics, Inc., Celgene Corporation
    Inventors: Archana BRAHMANDAM, Lucas James THOMPSON, Deborah MORTENSEN, Ellen FILVAROFF
  • Publication number: 20200262840
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: May 4, 2020
    Publication date: August 20, 2020
    Inventors: Jan ELSNER, Roy L. HARRIS, Branden Gingsee LEE, Deborah MORTENSEN, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Jingjing ZHAO
  • Patent number: 10683298
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: June 16, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Publication number: 20190077806
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: November 12, 2018
    Publication date: March 14, 2019
    Inventors: Jan ELSNER, Roy L. HARRIS, Branden Gingsee LEE, Deborah MORTENSEN, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Jingjing ZHAO
  • Patent number: 10167290
    Abstract: Provided herein are methods for the preparation of substituted pyrazino[2,3-b]pyrazines of the formula (II): the method comprising contacting a compound of formula (VI): with R1—Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R3, Y, the palladium catalyst and the base are as defined herein.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: January 1, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Publication number: 20170342080
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: August 18, 2017
    Publication date: November 30, 2017
    Inventors: Jan ELSNER, Roy L. HARRIS, Branden Gingsee LEE, Deborah MORTENSEN, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Jingjing ZHAO
  • Patent number: 9783505
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: October 10, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony Calabrese, Brandon Wade Whitefield, Brydon Bennett, Daniel Cashion, Deborah Mortensen, Dehua Huang, Eduardo Torres, Jason Parnes, John Sapienza, Joshua Hansen, Katerina Leftheris, Matthew Correa, Maria Mercedes Delgado, Raj K. Raheja, Sogole Bahmanyar, Sayee Hegde, Stephen Norris, Veronique Plantevin-Krenitsky
  • Patent number: 9771371
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: September 26, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Patent number: 9557338
    Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: January 31, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Weiming Xu, Deborah Mortensen, Shuichan Xu, Kimberly Elizabeth Fultz
  • Patent number: 9556126
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 31, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony Calabrese, Brandon Wade Whitefield, Brydon Bennett, Daniel Cashion, Deborah Mortensen, Dehua Huang, Eduardo Torres, Jason Parnes, John Sapienza, Joshua Hansen, Katerina Leftheris, Matthew Correa, Maria Mercedes Delgado, Raj K. Raheja, Sogole Bahmanyar, Sayee Hegde, Stephen Norris, Veronique Plantevin-Krenitsky
  • Publication number: 20160354374
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony CALABRESE, Brandon Wade WHITEFIELD, Brydon BENNETT, Daniel CASHION, Deborah MORTENSEN, Dehua HUANG, Eduardo TORRES, Jason PARNES, John SAPIENZA, Joshua HANSEN, Katerina LEFTHERIS, Matthew CORREA, Maria Mercedes DELGADO, Raj K. RAHEJA, Sogole BAHMANYAR, Sayee HEGDE, Stephen NORRIS, Veronique PLANTEVIN-KRENITSKY
  • Publication number: 20160024101
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: October 5, 2015
    Publication date: January 28, 2016
    Inventors: Jan ELSNER, Kimberly Elizabeth FULTZ, Roy L. HARRIS, Branden Gingsee LEE, Loui MADAKAMUTIL, Deborah MORTENSEN, Rama K. NARLA, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, Sabita SANKAR, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Weiming XU, Jingjing ZHAO
  • Publication number: 20150362505
    Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.
    Type: Application
    Filed: August 26, 2015
    Publication date: December 17, 2015
    Inventors: Weiming Xu, Deborah Mortensen, Shuichan Xu, Kimberly Elizabeth Fultz
  • Patent number: 9193692
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Furthermore, provided herein are compounds having the following formulas (IV), (V), (VII) and (VIII): wherein R, R2, R3, R4, Hal and Hal2 are as defined herein, for preparation of the Heteroaryl Compounds.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: November 24, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Jan Elsner
  • Patent number: 9156798
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: October 13, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sogole Bahmanyar, Andrew Antony Calabrese, Daniel Cashion, Brian Edwin Cathers, Matthew Correa, Maria Mercedes Delgado, Joshua Hansen, Sayee Hegde, Dehua Huang, Katerina Leftheris, Deborah Mortensen, Stephen Norris, Patrick Papa, Jason Parnes, Veronique Plantevin-Krenitsky, Raj Kumar Raheja, John Sapienza, Eduardo Torres, Brandon Wade Whitefield
  • Patent number: 9155736
    Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: October 13, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Weiming Xu, Deborah Mortensen, Shuichan Xu, Kimberly Elizabeth Fultz
  • Publication number: 20150246890
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Application
    Filed: April 7, 2015
    Publication date: September 3, 2015
    Inventors: Sogole BAHMANYAR, Andrew Antony CALABRESE, Daniel CASHION, Brian Edwin CATHERS, Matthew CORREA, Maria Mercedes DELGADO, Joshua HANSEN, Sayee HEGDE, Dehua HUANG, Katerina LEFTHERIS, Deborah MORTENSEN, Stephen NORRIS, Patrick PAPA, Jason PARNES, Veronique PLANTEVIN-KRENITSKY, Raj Kumar RAHEJA, John SAPIENZA, Eduardo TORRES, Brandon Wade WHITEFIELD
  • Patent number: 9079900
    Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: July 14, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Marie Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip Pye, William Wei-Hwa Leong, Jan Elsner, Anusuya Choudhury
  • Publication number: 20150175557
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Application
    Filed: December 19, 2014
    Publication date: June 25, 2015
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony CALABRESE, Brandon Wade WHITEFIELD, Brydon BENNETT, Daniel CASHION, Deborah MORTENSEN, Dehua HUANG, Eduardo TORRES, Jason PARNES, John SAPIENZA, Joshua HANSEN, Katerina LEFTHERIS, Matthew CORREA, Maria Mercedes DELGADO, Neil RAHEJA, Sami BAHMANYAR, Sayee HEGDE, Stephen NORRIS, Veronique PLANTEVIN-KRENITSKY
  • Publication number: 20150051397
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 19, 2015
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Jan Elsner